{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:09:51Z","timestamp":1781626191044,"version":"3.54.5"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver cirrhosis and pulmonary fibrosis are fibrotic disorders that arise from chronic wound-healing processes in response to persistent injury. Despite involving different organs, both conditions share pathophysiologic mechanisms, such as fibroblast-to-myofibroblast transformation, extracellular matrix deposition, and impaired remodeling. These overlapping pathways suggest a common fibrogenic network that extends beyond the organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Text<\/jats:title>\n                    <jats:p>In cirrhosis, hepatocyte necrosis and chronic inflammation activate hepatic stellate cells that later differentiate into myofibroblasts and produce an altered extracellular matrix. Initially, matrix metalloproteinases counterbalance fibrosis. However, their activity is progressively inhibited by tissue inhibitors of metalloproteinases leading to excessive scarring, and regenerative nodules. Similarly, persistent alveolar epithelial injury disrupts regenerative capacity, causing maladaptive repair in pulmonary fibrosis. Fibrogenic mediators, particularly transforming growth factor-\u03b2 and platelet-derived growth factor, drive fibroblast-to-myofibroblast differentiation and epithelial-mesenchymal transition. The resulting dense extracellular matrix creates a positive feedback loop that perpetuates fibrosis, leading to microscopic honeycombing and the histopathological pattern of usual interstitial pneumonia. Genetic and environmental factors cause the development of both conditions. Telomerase mutations and shortened telomeres predispose to cirrhosis and idiopathic pulmonary fibrosis. Smoking, hepatitis B and C are environmental factors for cirrhosis. On the other hand, epstein-barr virus, cytomegalovirus, and hepatitis C virus are responsible for pulmonary fibrosis. Both diseases promote vasoconstriction, leading to portal hypertension in the liver and pulmonary hypertension in the lungs. Transforming growth factor-\u03b2 plays a dual role in carcinogenesis, acting as a tumor suppressor in early stages but later acquires tumor-promoting properties in both diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cirrhosis and pulmonary fibrosis share molecular and cellular processes leading to fibrosis, vascular remodeling and malignant transformation in both diseases. Recognizing these overlapping mechanisms may help us better understand disease processes and guide development of targeted treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07449-4","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:14:57Z","timestamp":1766747697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The intersection of liver cirrhosis and pulmonary fibrosis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-2689","authenticated-orcid":false,"given":"Esref Alperen","family":"Bayraktar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"Suppl 2","key":"7449_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1440-1746.2011.07002.x","volume":"27","author":"K Iwaisako","year":"2012","unstructured":"Iwaisako K, Brenner DA, Kisseleva T. What\u2019s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012, Mar;27(Suppl 2):65\u201368.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"7449_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/modpathol.3880119","volume":"13","author":"L Ferrell","year":"2000","unstructured":"Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Mod Pathol. 2000, Jun;13(6):679\u2013704.","journal-title":"Mod Pathol"},{"issue":"5","key":"7449_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/jcp.31.5.395","volume":"31","author":"PP Anthony","year":"1978","unstructured":"Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 1978, May;31(5):395\u2013414.","journal-title":"J Clin Pathol"},{"issue":"9615","key":"7449_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008, Mar, 8;371(9615):838\u201351.","journal-title":"Lancet"},{"issue":"3","key":"7449_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40139-013-0020-0","volume":"1","author":"M Fausther","year":"2013","unstructured":"Fausther M, Lavoie EG, Dranoff JA. Contribution of myofibroblasts of different origins to liver fibrosis. Curr Pathobiol Rep. 2013, Sep, 1;1(3):225\u201330.","journal-title":"Curr Pathobiol Rep"},{"issue":"3","key":"7449_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-2001-17556","volume":"21","author":"D Schuppan","year":"2001","unstructured":"Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001, Aug;21(3):351\u201372.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"7449_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","volume":"134","author":"M Selman","year":"2001","unstructured":"Selman M, King TE, Pardo A. American thoracic society, European respiratory society, American college of chest physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001, Jan, 16;134(2):136\u201351.","journal-title":"Ann Intern Med"},{"key":"7449_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","volume":"9","author":"PJ Wolters","year":"2014","unstructured":"Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157\u201379.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"7449_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","volume":"19","author":"G Sgalla","year":"2018","unstructured":"Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018, Feb, 22;19(1):32.","journal-title":"Respir Res"},{"issue":"6","key":"7449_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1083\/jcb.200704042","volume":"179","author":"PJ Wipff","year":"2007","unstructured":"Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. The J Cell Biol. 2007, Dec, 17;179(6):1311\u201323.","journal-title":"The J Cell Biol"},{"issue":"5","key":"7449_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1513\/pats.200601-008AW","volume":"3","author":"D Sheppard","year":"2006","unstructured":"Sheppard D. Transforming growth factor \u03b2. Proc Am Thorac Soc. 2006, Jul;3(5):413\u201317.","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"7449_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/mi.2008.85","volume":"2","author":"M Wilson","year":"2009","unstructured":"Wilson M, Wynn T. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009, Mar;2(2):103\u201321.","journal-title":"Mucosal Immunol"},{"issue":"12","key":"7449_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/jcm7120476","volume":"7","author":"O Kalchiem-Dekel","year":"2018","unstructured":"Kalchiem-Dekel O, Galvin JR, Burke AP, Atamas SP, Todd NW. Interstitial lung disease and pulmonary fibrosis: a practical approach for General medicine physicians with focus on the medical history. J Clin Med. 2018, Nov, 24;7(12):476.","journal-title":"J Clin Med"},{"issue":"3","key":"7449_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0163-7258(92)90055-5","volume":"53","author":"R Gebhardt","year":"1992","unstructured":"Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther. 1992;53(3):275\u2013354.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"7449_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.immuni.2019.08.017","volume":"51","author":"J Bonnardel","year":"2019","unstructured":"Bonnardel J, T\u2019Jonck W, Gaublomme D, Browaeys R, Scott CL, Martens L, et al. Stellate cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on monocytes colonizing the liver macrophage niche. Immunity. 2019, Oct;51(4):638\u201354.e9.","journal-title":"Immunity"},{"issue":"32","key":"7449_CR16","doi-asserted-by":"publisher","first-page":"E3297","DOI":"10.1073\/pnas.1400062111","volume":"111","author":"K Iwaisako","year":"2014","unstructured":"Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014, Aug, 12;111(32):E3297\u20133305.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7449_CR17","first-page":"G137","volume":"277","author":"MS Thimgan","year":"1999","unstructured":"Thimgan MS, Yee HF. Quantitation of rat hepatic stellate cell contraction: stellate cells\u2019 contribution to sinusoidal resistance. Am J Physiol-Gastr L. 1999, Jul;277(1):G137\u201343.","journal-title":"Am J Physiol-Gastr L"},{"issue":"6","key":"7449_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/hep.1840150603","volume":"15","author":"RF McGuire","year":"1992","unstructured":"McGuire RF, Bissell DM, Boyles J, Roll FJ. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology. 1992, Jun;15(6):989\u201397.","journal-title":"Hepatology"},{"issue":"2","key":"7449_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1148\/radiol.2392041968","volume":"239","author":"WR Webb","year":"2006","unstructured":"Webb WR. Thin-section ct of the secondary pulmonary lobule: anatomy and the image\u2013the 2004 Fleischner lecture. Radiology. 2006, May;239(2):322\u201338.","journal-title":"Radiology"},{"issue":"2","key":"7449_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/thx.13.2.110","volume":"13","author":"L Reid","year":"1958","unstructured":"Reid L. The secondary lobule in the adult human lung, with special reference to its appearance in Bronchograms *. Thorax. 1958, Jun;13(2):110\u201315.","journal-title":"Thorax"},{"key":"7449_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2022, Jan, 24;17:515\u201346.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"7449_CR22","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3390\/ijms21072269","volume":"21","author":"T Parimon","year":"2020","unstructured":"Parimon T, Yao C, Stripp BR, Noble PW, Chen P. Alveolar epithelial type ii cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci. 2020, Mar, 25;21(7):2269.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"7449_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17476348.2019.1623028","volume":"13","author":"J Snijder","year":"2019","unstructured":"Snijder J, Peraza J, Padilla M, Capaccione K, Salvatore MM. Pulmonary fibrosis: a disease of alveolar collapse and collagen deposition. Expert Rev Respir Med. 2019, Jul;13(7):615\u201319.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"7449_CR24","first-page":"1","volume":"11","author":"M Aghaei","year":"2020","unstructured":"Aghaei M, Dastghaib S, Aftabi S, Aghanoori MR, Alizadeh J, Mokarram P, et al. The er Stress\/UPR Axis in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Life (Basel). 2020, Dec, 22;11(1):1.","journal-title":"Life (Basel)"},{"key":"7449_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.med.55.091902.103810","volume":"55","author":"VJ Thannickal","year":"2004","unstructured":"Thannickal VJ, Toews GB, White ES, Lynch JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 2004;55:395\u2013417.","journal-title":"Annu. Rev. Med"},{"issue":"4","key":"7449_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020, Apr, 3;9(4):875.","journal-title":"Cells"},{"issue":"4","key":"7449_CR27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1378\/chest.06-2568","volume":"132","author":"CJ Scotton","year":"2007","unstructured":"Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007, Oct;132(4):1311\u201321.","journal-title":"Chest"},{"issue":"3","key":"7449_CR28","doi-asserted-by":"publisher","first-page":"E593","DOI":"10.3390\/ijms20030593","volume":"20","author":"B Ballester","year":"2019","unstructured":"Ballester B, Milara J, Cortijo J. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci. 2019, Jan, 30;20(3):E593.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"7449_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021, Mar;18(3):151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7449_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv. Drug Deliv. Rev. 2017, Nov, 1;121:27\u201342.","journal-title":"Adv. Drug Deliv. Rev"},{"issue":"3","key":"7449_CR31","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1002\/j.2040-4603.2022.tb00222.x","volume":"12","author":"T Guo","year":"2022","unstructured":"Guo T, He C, Venado A, Zhou Y. Extracellular matrix stiffness in lung health and disease. Compr Physiol. 2022, Jun, 29;12(3):3523\u201358.","journal-title":"Compr Physiol"},{"issue":"13","key":"7449_CR32","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/ijms23136894","volume":"23","author":"L Chuli\u00e1-Peris","year":"2022","unstructured":"Chuli\u00e1-Peris L, Carreres-Rey C, Gabasa M, Alcaraz J, Carretero J, Pereda J. Matrix metalloproteinases and their inhibitors in pulmonary fibrosis: EMMPRIN\/CD147 comes into play. Int J Mol Sci. 2022, Jun, 21;23(13):6894.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7449_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/cells9051212","volume":"9","author":"E Geervliet","year":"2020","unstructured":"Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020, May, 13;9(5):1212.","journal-title":"Cells"},{"key":"7449_CR34","doi-asserted-by":"crossref","unstructured":"Cunningham RP, Porat-Shliom N. Liver zonation \u2013 revisiting old questions with new technologies. Front Physiol [Internet]. 2021;12. Available from:cited 2023 Apr 16.https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.732929.","DOI":"10.3389\/fphys.2021.732929"},{"key":"7449_CR35","doi-asserted-by":"crossref","unstructured":"Dutta S, Mishra SP, Sahu AK, Mishra K, Kashyap P, Sahu B, et al. Hepatocytes and their role in metabolism [internet]. Drug metabolism. intechopen. 2021.Available from cited 2023 Apr 16]. https:\/\/www.intechopen.com\/chapters\/78184.","DOI":"10.5772\/intechopen.99083"},{"issue":"2","key":"7449_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/cells9020420","volume":"9","author":"A Messina","year":"2020","unstructured":"Messina A, Luce E, Hussein M, Dubart-Kupperschmitt A. Pluripotent-stem-cell-derived hepatic cells: hepatocytes and organoids for liver therapy and regeneration. Cells. 2020, Feb, 12;9(2):420.","journal-title":"Cells"},{"issue":"4","key":"7449_CR37","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.3390\/ijms12042434","volume":"12","author":"J Li","year":"2011","unstructured":"Li J, Fan R, Zhao S, Liu L, Guo S, Wu N, et al. Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells. Int J Mol Sci. 2011;12(4):2434\u201347.","journal-title":"Int J Mol Sci"},{"key":"7449_CR38","first-page":"1","volume":"7","author":"CR Gandhi","year":"2012","unstructured":"Gandhi CR. Oxidative stress and hepatic stellate cells: a paradoxical relationship. Trends Cell Mol Biol. 2012;7:1\u201310.","journal-title":"Trends Cell Mol Biol"},{"issue":"3","key":"7449_CR39","doi-asserted-by":"publisher","first-page":"e00405","DOI":"10.1002\/prp2.405","volume":"6","author":"S Kamata","year":"2018","unstructured":"Kamata S, Fujino N, Yamada M, Grime K, Suzuki S, Ota C, et al. Expression of cytochrome P450 mRNAs in type II alveolar cells from subjects with chronic obstructive pulmonary disease. Pharmacol Res Perspect. 2018, May, 21;6(3):e00405.","journal-title":"Pharmacol Res Perspect"},{"issue":"13","key":"7449_CR40","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3390\/cells11132095","volume":"11","author":"P Confalonieri","year":"2022","unstructured":"Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B, et al. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022, Jun, 30;11(13):2095.","journal-title":"Cells"},{"issue":"1","key":"7449_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/arm91010005","volume":"91","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang J. Cellular and molecular mechanisms in idiopathic pulmonary fibrosis. Adv Respir Med. 2023, Jan, 31;91(1):26\u201348.","journal-title":"Adv Respir Med"},{"key":"7449_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.matbio.2018.03.015","volume":"68\u201369","author":"A Burman","year":"2018","unstructured":"Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol. 2018, Aug;68\u201369:355\u201365.","journal-title":"Matrix Biol"},{"issue":"2","key":"7449_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005, Feb, 1;115(2):209\u201318.","journal-title":"J. Clin. Invest"},{"issue":"2","key":"7449_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","volume":"18","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014, May;18(2):281\u201391.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"7449_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cld.604","volume":"8","author":"J Gracia-Sancho","year":"2016","unstructured":"Gracia-Sancho J, Laleman W. Mechanisms of portal hypertension: bench to bedside. Clin Liver Dis (Hoboken). 2016, Dec, 30;8(6):160\u201366.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"Suppl 1","key":"7449_CR46","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","volume":"75","author":"C Engelmann","year":"2021","unstructured":"Engelmann C, Cl\u00e0ria J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021, Jul;75(Suppl 1):S49\u201366.","journal-title":"J Hepatol"},{"issue":"10308","key":"7449_CR47","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gin\u00e8s","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes JG, Sol\u00e0 E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021, Oct, 9;398(10308):1359\u201376.","journal-title":"Lancet"},{"issue":"9930","key":"7449_CR48","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014, May, 17;383(9930):1749\u201361.","journal-title":"Lancet"},{"issue":"4","key":"7449_CR49","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.27343","volume":"61","author":"M Fernandez","year":"2015","unstructured":"Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology. 2015, Mar, 25;61(4):1406.","journal-title":"Hepatology"},{"issue":"1","key":"7449_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bph.15036","volume":"178","author":"K Rajagopal","year":"2021","unstructured":"Rajagopal K, Bryant AJ, Sahay S, Wareing N, Zhou Y, Pandit LM, et al. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. Br J Pharmacol. 2021, Jan;178(1):172\u201386.","journal-title":"Br J Pharmacol"},{"key":"7449_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12931-020-01570-2","volume":"21","author":"G Ruffenach","year":"2020","unstructured":"Ruffenach G, Hong J, Vaillancourt M, Medzikovic L, Eghbali M. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res. 2020;21:303.","journal-title":"Respir Res"},{"issue":"33","key":"7449_CR52","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.4254\/wjh.v8.i33.1419","volume":"8","author":"YQ Huang","year":"2016","unstructured":"Huang YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol. 2016, Nov, 28;8(33):1419\u201341.","journal-title":"World J Hepatol"},{"issue":"3","key":"7449_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.32074\/1591-951X-245","volume":"113","author":"S Sarcognato","year":"2021","unstructured":"Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021, Jun, 1;113(3):170\u201384.","journal-title":"Pathologica"},{"issue":"2","key":"7449_CR54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1165\/rcmb.2014-0078OC","volume":"52","author":"D Lutz","year":"2015","unstructured":"Lutz D, Gazdhar A, Lopez-Rodriguez E, Ruppert C, Mahavadi P, G\u00fcnther A, et al. Alveolar derecruitment and collapse induration as crucial mechanisms in lung injury and fibrosis. Am J Respir Cell Mol Biol. 2015, Feb;52(2):232\u201343.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"7449_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12890-016-0245-x","volume":"16","author":"S Piciucchi","year":"2016","unstructured":"Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, et al. From \u201ctraction bronchiectasis\u201d to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? Bmc Pulm Med. 2016, May, 23;16:87.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"7449_CR56","doi-asserted-by":"publisher","first-page":"e58658","DOI":"10.1371\/journal.pone.0058658","volume":"8","author":"MA Seibold","year":"2013","unstructured":"Seibold MA, Smith RW, Urbanek C, Groshong SD, Cosgrove GP, Brown KK, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One. 2013, Mar, 20;8(3):e58658.","journal-title":"PLoS One"},{"issue":"23","key":"7449_CR57","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","volume":"20","author":"WC Zhou","year":"2014","unstructured":"Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014, Jun, 21;20(23):7312\u201324.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"7449_CR58","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jcmgh.2015.06.011","volume":"1","author":"C Bocca","year":"2015","unstructured":"Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and fibrogenesis in chronic liver diseases. Cell Mol Gastroenterol Hepatol. 2015, Jul, 13;1(5):477\u201388.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"7449_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jcmgh.2015.09.005","volume":"1","author":"KJ Roth","year":"2015","unstructured":"Roth KJ, Copple BL. Role of hypoxia-inducible factors in the development of liver fibrosis. Cell Mol Gastroenterol Hepatol. 2015, Sep, 25;1(6):589\u201397.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"7449_CR60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1055\/s-0030-1255355","volume":"30","author":"O Rosmorduc","year":"2010","unstructured":"Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis. 2010, Aug;30(3):258\u201370.","journal-title":"Semin Liver Dis"},{"key":"7449_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/dmr-21-87","volume":"5","author":"KL Poulsen","year":"2022","unstructured":"Poulsen KL, Ross Ck C-D, Chaney JK, Nagy LE. Role of the chemokine system in liver fibrosis: a narrative review. Dig Med Res. 2022, Jun;5:30.","journal-title":"Dig Med Res"},{"issue":"2","key":"7449_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"T Wynn","year":"2008","unstructured":"Wynn T. Cellular and molecular mechanisms of fibrosis. The J Pathol. 2008, Jan;214(2):199\u2013210.","journal-title":"The J Pathol"},{"key":"7449_CR63","doi-asserted-by":"publisher","first-page":"918771","DOI":"10.3389\/fphar.2022.918771","volume":"13","author":"H Ma","year":"2022","unstructured":"Ma H, Liu S, Li S, Xia Y. Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis. Front Pharmacol. 2022, Jun, 3;13:918771.","journal-title":"Front Pharmacol"},{"issue":"6","key":"7449_CR64","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/cells11060986","volume":"11","author":"F Schramm","year":"2022","unstructured":"Schramm F, Schaefer L, Wygrecka M. EGFR signaling in lung fibrosis. Cells. 2022, Mar, 14;11(6):986.","journal-title":"Cells"},{"key":"7449_CR65","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, et al. Targeting fibrosis: mechanisms and clinical trials. Signal Transduct Target Ther. 2022, Jun, 30;7:206.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"7449_CR66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","volume":"55","author":"S Kolahian","year":"2016","unstructured":"Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2016, Sep;55(3):309\u201322.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"7449_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1164\/rccm.200804-550OC","volume":"178","author":"JT Cronkhite","year":"2008","unstructured":"Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008, Oct, 1;178(7):729\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"7449_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3748\/wjg.v21.i2.379","volume":"21","author":"L Carulli","year":"2015","unstructured":"Carulli L. Telomere shortening as genetic risk factor of liver cirrhosis. World J Gastroenterol. 2015, Jan, 14;21(2):379\u201383.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"7449_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/bbrc.1995.1774","volume":"211","author":"T Kitada","year":"1995","unstructured":"Kitada T, Seki S, Kawakita N, Kuroki T, Monna T. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun. 1995, Jun, 6;211(1):33\u201339.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5456","key":"7449_CR70","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.287.5456.1253","volume":"287","author":"KL Rudolph","year":"2000","unstructured":"Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 2000, Feb, 18;287(5456):1253\u201358.","journal-title":"Science"},{"issue":"13","key":"7449_CR71","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa066157","volume":"356","author":"MY Armanios","year":"2007","unstructured":"Armanios MY, Chen JJL, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007, Mar, 29;356(13):1317\u201326.","journal-title":"N Engl J Med"},{"key":"7449_CR72","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fmed.2017.00154","volume":"4","author":"A Kaur","year":"2017","unstructured":"Kaur A, Mathai SK, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med (Lausanne). 2017, Sep, 25;4:154.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"7449_CR73","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-019-0165-3","volume":"16","author":"JC Nault","year":"2019","unstructured":"Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019, Sep, 1;16(9):544\u201358.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"18","key":"7449_CR74","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0701009104","volume":"104","author":"KD Tsakiri","year":"2007","unstructured":"Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci, India, Sect B Biol Sci. 2007, May;104(18):7552\u201357.","journal-title":"Proc Natl Acad Sci, India, Sect B Biol Sci"},{"issue":"35","key":"7449_CR75","doi-asserted-by":"publisher","first-page":"13051","DOI":"10.1073\/pnas.0804280105","volume":"105","author":"JK Alder","year":"2008","unstructured":"Alder JK, Chen JJL, Lancaster L, Danoff S, Chih SS, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008, Sep, 2;105(35):13051\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"7449_CR76","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.26089","volume":"56","author":"L Carulli","year":"2012","unstructured":"Carulli L, Dei Cas A, Nascimbeni F. Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomere involvement. Hepatology. 2012, Nov;56(5):2001\u201303.","journal-title":"Hepatology"},{"issue":"1","key":"7449_CR77","first-page":"11","volume":"2","author":"L Carulli","year":"2014","unstructured":"Carulli L, Anzivino C, Bertolotti M, Loria P, Richeldi L, Cerri S. Lung fibrosis, bone marrow fibrosis and liver cirrhosis: a short telomere syndrome or a casual association? Case Rep In Intern Med. 2014, Sep, 12;2(1):11.","journal-title":"Case Rep In Intern Med"},{"key":"7449_CR78","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.8209.1","volume":"5","author":"C Daccord","year":"2016","unstructured":"Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res. 2016, May, 31;5:F1000. Faculty Rev-1046.","journal-title":"F1000Res"},{"issue":"9807","key":"7449_CR79","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King","year":"2011","unstructured":"King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011, Dec, 3;378(9807):1949\u201361.","journal-title":"Lancet"},{"issue":"1","key":"7449_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1242\/dmm.010736","volume":"6","author":"JA Kropski","year":"2013","unstructured":"Kropski JA, Lawson WE, Young LR, Blackwell TS. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech. 2013, Jan;6(1):9\u201317.","journal-title":"Dis Model Mech"},{"key":"7449_CR81","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/COPD.S19599","volume":"6","author":"P Geraghty","year":"2011","unstructured":"Geraghty P, Wallace A, D\u2019Armiento JM. Induction of the unfolded protein response by cigarette smoke is primarily an activating transcription factor 4-C\/EBP homologous protein mediated process. Int J Chron Obstruct Pulmon Dis. 2011;6:309\u201319.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"7449_CR82","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jcm6010002","volume":"6","author":"A Betensley","year":"2016","unstructured":"Betensley A, Sharif R, Karamichos D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. J Clin Med. 2016, Dec, 26;6(1):2.","journal-title":"J Clin Med"},{"issue":"38","key":"7449_CR83","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.3748\/wjg.v12.i38.6098","volume":"12","author":"AR El-Zayadi","year":"2006","unstructured":"El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol. 2006, Oct, 14;12(38):6098\u2013101.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"7449_CR84","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jceh.2021.07.016","volume":"11","author":"M Premkumar","year":"2021","unstructured":"Premkumar M, Tobacco AA. Cigarettes, and the liver: the smoking gun. J Clin Exp Hepatol. 2021, Dec;11(6):700\u201312.","journal-title":"J Clin Exp Hepatol"},{"key":"7449_CR85","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1183\/09031936.06.00087005","volume":"27","author":"M Morl\u00e1","year":"2006","unstructured":"Morl\u00e1 M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti A. Telomere shortening in smokers with and without COPD. Eur Respir J: Off J Eur Soc For Clin Respir Physiol. 2006, Apr, 1;27:525\u201328.","journal-title":"Eur Respir J: Off J Eur Soc For Clin Respir Physiol"},{"issue":"8","key":"7449_CR86","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1164\/rccm.200509-1374OC","volume":"174","author":"T Tsuji","year":"2006","unstructured":"Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006, Oct, 15;174(8):886\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"7449_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/jhep.2001.25385","volume":"34","author":"F Pessione","year":"2001","unstructured":"Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology. 2001;34(1):121\u201325.","journal-title":"Hepatology"},{"issue":"11","key":"7449_CR88","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/oxfordjournals.aje.a009060","volume":"145","author":"MW Yu","year":"1997","unstructured":"Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997, Jun, 1;145(11):1039\u201347.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"7449_CR89","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988, Jun;8(3):493\u201396.","journal-title":"Hepatology"},{"issue":"6","key":"7449_CR90","doi-asserted-by":"publisher","first-page":"E1358","DOI":"10.3390\/ijms20061358","volume":"20","author":"T Kanda","year":"2019","unstructured":"Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019, Mar, 18;20(6):E1358.","journal-title":"Int J Mol Sci"},{"issue":"9055","key":"7449_CR91","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997, Mar, 22;349(9055):825\u201332.","journal-title":"Lancet"},{"issue":"4","key":"7449_CR92","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1513\/pats.200512-131TK","volume":"3","author":"VS Taskar","year":"2006","unstructured":"Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006, Jun;3(4):293\u201398.","journal-title":"Proc Am Thorac Soc"},{"issue":"10","key":"7449_CR93","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.rmed.2007.02.027","volume":"101","author":"T Gustafson","year":"2007","unstructured":"Gustafson T, Dahlman-H\u00f6glund A, Nilsson K, Str\u00f6m K, Tornling G, Tor\u00e9n K. Occupational exposure and severe pulmonary fibrosis. Respir Med. 2007, Oct, 1;101(10):2207\u201312.","journal-title":"Respir Med"},{"issue":"11","key":"7449_CR94","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1172\/JCI74368","volume":"124","author":"VJ Thannickal","year":"2014","unstructured":"Thannickal VJ, Zhou Y, Gaggar A, Duncan SR. Fibrosis: ultimate and proximate causes. J. Clin. Invest. 2014, Nov, 3;124(11):4673\u201377.","journal-title":"J. Clin. Invest"},{"issue":"1","key":"7449_CR95","doi-asserted-by":"publisher","first-page":"e000380","DOI":"10.1136\/bmjgast-2020-000380","volume":"7","author":"CS Alvarez","year":"2020","unstructured":"Alvarez CS, Hern\u00e1ndez E, Escobar K, Villagr\u00e1n CI, Kroker-Lobos MF, Rivera-Andrade A, et al. Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case\u2013control study. BMJ Open Gastroenterol. 2020, Jul, 7;7(1):e000380.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"7449_CR96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cld.2018.09.013","volume":"23","author":"MR Lucey","year":"2019","unstructured":"Lucey MR. Alcohol-associated cirrhosis. Clin Liver Dis. 2019, Feb;23(1):115\u201326.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"7449_CR97","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","volume":"245","author":"D Dhar","year":"2020","unstructured":"Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (maywood). 2020, Jan;245(2):96\u2013108.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"7449_CR98","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, Jun;132(7):2557\u201376.","journal-title":"Gastroenterology"},{"key":"7449_CR99","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of Cancer-associated Fibroblasts and fibrosis in liver Cancer. Annu Rev Pathol. 2017, Jan, 24;12:153\u201386.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"7449_CR100","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/hepr.12356","volume":"45","author":"N Lin","year":"2015","unstructured":"Lin N, Chen Z, Lu Y, Li Y, Hu K, Xu R. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol Res. 2015, Mar;45(3):326\u201336.","journal-title":"Hepatol Res"},{"issue":"5","key":"7449_CR101","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","volume":"135","author":"K Taura","year":"2008","unstructured":"Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008, Nov;135(5):1729\u201338.","journal-title":"Gastroenterology"},{"issue":"5","key":"7449_CR102","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jhep.2004.01.027","volume":"40","author":"T Torimura","year":"2004","unstructured":"Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004, May;40(5):799\u2013807.","journal-title":"J Hepatol"},{"key":"7449_CR103","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75\u201397.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"13","key":"7449_CR104","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009, Dec, 21;206(13):3015\u201329.","journal-title":"J Exp Med"},{"issue":"6","key":"7449_CR105","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/hep.20488","volume":"40","author":"MC Yu","year":"2004","unstructured":"Yu MC, Chen CH, Liang X, Wang L, Gandhi CR, Fung JJ, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1\u2013mediated T-cell apoptosis in mice. Hepatology. 2004;40(6):1312\u201321.","journal-title":"Hepatology"},{"issue":"5","key":"7449_CR106","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000341704","volume":"30","author":"NM Meindl-Beinker","year":"2012","unstructured":"Meindl-Beinker NM, Matsuzaki K, Dooley S. TGF-\u03b2 signaling in onset and progression of hepatocellular carcinoma. Dig Dis. 2012;30(5):514\u201323.","journal-title":"Dig Dis"},{"issue":"9","key":"7449_CR107","first-page":"2127","volume":"12","author":"M Saitoh","year":"2022","unstructured":"Saitoh M. Epithelial-mesenchymal transition by synergy between transforming growth Factor-\u03b2 and growth factors in cancer progression. Diagn (Basel). 2022, Sep, 1;12(9):2127.","journal-title":"Diagn (Basel)"},{"issue":"5","key":"7449_CR108","doi-asserted-by":"publisher","first-page":"E1294","DOI":"10.3390\/ijms19051294","volume":"19","author":"L Caja","year":"2018","unstructured":"Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, et al. TGF-\u03b2 and the tissue microenvironment: relevance in fibrosis and cancer. Int J Mol Sci. 2018, Apr, 26;19(5):E1294.","journal-title":"Int J Mol Sci"},{"key":"7449_CR109","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12885-015-1196-y","volume":"15","author":"CHC Sukowati","year":"2015","unstructured":"Sukowati CHC, Anfuso B, Croc\u00e9 LS, Tiribelli C. The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer. 2015, Mar, 27;15:188.","journal-title":"BMC Cancer"},{"issue":"30","key":"7449_CR110","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.3748\/wjg.v22.i30.6841","volume":"22","author":"N Kubo","year":"2016","unstructured":"Kubo N, Araki K, Kuwano H, Shirabe K. Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol. 2016, Aug, 14;22(30):6841\u201350.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"7449_CR111","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms20071723","volume":"20","author":"J Baglieri","year":"2019","unstructured":"Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019, Apr, 7;20(7):1723.","journal-title":"Int J Mol Sci"},{"issue":"39","key":"7449_CR112","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.3748\/wjg.v24.i39.4436","volume":"24","author":"JM O\u2019Rourke","year":"2018","unstructured":"O\u2019Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018, Oct, 21;24(39):4436\u201347.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"7449_CR113","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1440-1827.1995.tb03417.x","volume":"45","author":"H Matsushita","year":"1995","unstructured":"Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995, Dec;45(12):925\u201332.","journal-title":"Pathol Int"},{"issue":"12","key":"7449_CR114","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.rmed.2007.07.012","volume":"101","author":"I Le Jeune","year":"2007","unstructured":"Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the Uk. Respir Med. 2007, Dec;101(12):2534\u201340.","journal-title":"Respir Med"},{"issue":"5","key":"7449_CR115","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1440-1843.2009.01547.x","volume":"14","author":"Y Ozawa","year":"2009","unstructured":"Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in ipf. Respirology. 2009, Jul;14(5):723\u201328.","journal-title":"Respirology"},{"issue":"1","key":"7449_CR116","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","volume":"147","author":"S Tomassetti","year":"2015","unstructured":"Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015, Jan;147(1):157\u201364.","journal-title":"Chest"},{"issue":"18","key":"7449_CR117","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.21037\/atm-21-4224","volume":"9","author":"N Li","year":"2021","unstructured":"Li N, Qiu L, Zeng C, Fang Z, Chen S, Song X, et al. Bioinformatic analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis. Ann Transl Med. 2021, Sep;9(18):1459.","journal-title":"Ann Transl Med"},{"issue":"10","key":"7449_CR118","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3390\/jcm8101547","volume":"8","author":"J Duitman","year":"2019","unstructured":"Duitman J, van den Ende T, Spek CA. Immune checkpoints as promising targets for the treatment of idiopathic pulmonary fibrosis? J Clin Med. 2019, Sep, 26;8(10):1547.","journal-title":"J Clin Med"},{"issue":"23","key":"7449_CR119","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.3390\/jcm10235562","volume":"10","author":"S Kronborg-White","year":"2021","unstructured":"Kronborg-White S, Madsen LB, Bendstrup E, Poletti V. PD-L1 expression in patients with idiopathic pulmonary fibrosis. J Clin Med. 2021, Nov, 26;10(23):5562.","journal-title":"J Clin Med"},{"issue":"10","key":"7449_CR120","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the TGF\u03b2 signalling pathway in disease. Nat Rev Drug Discov. 2012, Oct;11(10):790\u2013811.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"7449_CR121","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/ijms20061461","volume":"20","author":"T Kinoshita","year":"2019","unstructured":"Kinoshita T, Goto T. Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: a review. Int J Mol Sci. 2019, Mar, 22;20(6):1461.","journal-title":"Int J Mol Sci"},{"key":"7449_CR122","doi-asserted-by":"publisher","first-page":"668731","DOI":"10.3389\/fonc.2021.668731","volume":"11","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Gaggar S, G\u00f6genur I. Cancer-associated Fibroblasts and tumor-associated Macrophages in Cancer and Cancer immunotherapy. Front Oncol. 2021, May, 20;11:668731.","journal-title":"Front Oncol"},{"issue":"3","key":"7449_CR123","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1183\/09031936.00077309","volume":"35","author":"C Vancheri","year":"2010","unstructured":"Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010, Mar;35(3):496\u2013504.","journal-title":"Eur Respir J"},{"issue":"3","key":"7449_CR124","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.lungcan.2004.02.021","volume":"45","author":"H Ishii","year":"2004","unstructured":"Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004, Sep;45(3):325\u201337.","journal-title":"Lung Cancer"},{"issue":"1","key":"7449_CR125","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1465-9921-7-128","volume":"7","author":"AI Papaioannou","year":"2006","unstructured":"Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI. Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res. 2006;7(1):128.","journal-title":"Respir Res"},{"key":"7449_CR126","doi-asserted-by":"crossref","unstructured":"NADPH oxidases and cancer | clinical science | Portland Press [internet].[cited 2023 Apr 22]. Available from.https:\/\/portlandpress.com\/clinsci\/article\/128\/12\/863\/71192\/NADPH-oxidases-and-cancer.","DOI":"10.1042\/CS20140542"},{"issue":"10","key":"7449_CR127","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","volume":"114","author":"M Roerecke","year":"2019","unstructured":"Roerecke M, Vafaei A, Hasan OS, Chrystoja BR, Cruz M, Lee R, et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am J Gastroenterol. 2019, Oct;114(10):1574\u201386.","journal-title":"Am J Gastroenterol"},{"issue":"9603","key":"7449_CR128","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007, Dec, 8;370(9603):1915\u201322.","journal-title":"Lancet"},{"issue":"8","key":"7449_CR129","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016, Aug, 25;375(8):767\u201377.","journal-title":"N Engl J Med"},{"issue":"8","key":"7449_CR130","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJF, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022, Aug;7(8):724\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"7449_CR131","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.Eu, clinical practice guidelines panel: chair: EASL board representative: panel members: EASL recommendations on treatment of unstruct unstruct C: final update of the series\u2606. J Hepatol. 2020, Nov;73(5):1170\u2013218","journal-title":"J Hepatol"},{"issue":"2","key":"7449_CR132","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/egh.12.4","volume":"6","author":"A Brown","year":"2012","unstructured":"Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis\/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol. 2012, Apr;6(2):187\u201398.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"12","key":"7449_CR133","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17474124.2017.1361822","volume":"11","author":"M Okada","year":"2017","unstructured":"Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017, Dec;11(12):1095\u2013104.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"7449_CR134","doi-asserted-by":"crossref","unstructured":"Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981, Dec, 3;305(23):1371\u201374.","DOI":"10.1056\/NEJM198112033052302"},{"issue":"1","key":"7449_CR135","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","volume":"2","author":"SG Rodrigues","year":"2019","unstructured":"Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep. 2019, Dec, 20;2(1):100063.","journal-title":"JHEP Rep"},{"key":"7449_CR136","doi-asserted-by":"crossref","unstructured":"Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018, Oct, 29;2018(10):CD011510.","DOI":"10.1002\/14651858.CD011510.pub2"},{"issue":"8","key":"7449_CR137","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ueg2.12300","volume":"10","author":"L Weichselbaum","year":"2022","unstructured":"Weichselbaum L, Lepida A, Marot A, Tr\u00e9po E, Moreno C, Deltenre P. Salvage transjugular intrahepatic portosystemic shunt in patients with cirrhosis and refractory variceal bleeding: a systematic review with meta-analysis. U Eur Gastroenterol J. 2022, Oct, 10;10(8):874\u201387.","journal-title":"U Eur Gastroenterol J"},{"key":"7449_CR138","unstructured":"Conatus Pharmaceuticals Inc. A multicenter, double-blind, randomized trial of IDN-6556 in subjects who had hepatitis C virus (HCV) reinfection and liver fibrosis following orthotopic liver transplantation for chronic HCV infection and who subsequently achieved a sustained virologic response following anti-HCV therapy [Internet]. clinicaltrials.gov; Report No: NCT02138253. Available from: 2019, Nov.[cited 2025 Sep 15] https:\/\/clinicaltrials.gov\/study\/NCT02138253."},{"key":"7449_CR139","unstructured":"Double-Blind CTAA, Randomized. Placebo-controlled clinical trial to assess the efficacy & safety of oral GKT137831 in patients with primary biliary cholangitis receiving ursodeoxycholic acid and with persistently elevated alkaline phosphatase [Internet]. clinicaltrials.gov; Report No.: nCT03226067. Available from: 2022, Jun. [cited 2025 Sep 15]https:\/\/clinicaltrials.gov\/study\/NCT03226067."},{"issue":"7","key":"7449_CR140","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/liv.15596","volume":"43","author":"P Invernizzi","year":"2023","unstructured":"Invernizzi P, Carbone M, Jones D, Levy C, Little N, Wiesel P, et al. Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial. Liver Int. 2023;43(7):1507\u201322.","journal-title":"Liver Int"},{"key":"7449_CR141","unstructured":"Kimura K. Phase I\/IIa clinical trial for patients with hepatitis C or B virus derived liver cirrhosis by CBP\/\u03b2 catenin inhibitor PRI-724 [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Sep 15]. Report No: NCT03620474. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03620474."},{"key":"7449_CR142","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.ebiom.2022.104069","volume":"80","author":"K Kimura","year":"2022","unstructured":"Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP\/\u03b2-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1\/2a study. EBioMedicine. 2022, Jun;80:104069.","journal-title":"EBioMedicine"},{"key":"7449_CR143","unstructured":"Randomized B-MSA, Double-Blind P-C. Parallel group, multiple dose study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of BMS-986263 in adults with advanced hepatic fibrosis after virologic cure of hepatitis C [internet]. clinicaltrials.gov; Report No- NCT03420768. Available from: 2022, Feb.cited 2025 Sep 15.https:\/\/clinicaltrials.gov\/study\/NCT03420768."},{"issue":"4","key":"7449_CR144","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hep.32181","volume":"75","author":"EJ Lawitz","year":"2022","unstructured":"Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022, Apr;75(4):912\u201323.","journal-title":"Hepatology"},{"issue":"7","key":"7449_CR145","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.cgh.2022.05.056","volume":"21","author":"X Cai","year":"2023","unstructured":"Cai X, Liu X, Xie W, Ma A, Tan Y, Shang J, et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial. Clin Gastroenterol Hepatol. 2023, Jul;21(7):1893\u2013901.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7449_CR146","unstructured":"Shanghai Genomics, Inc. Randomed and double-blinded phase II clinical trial of hydronidone Capsules(F351) in patients with liver fibrosis induced by HBV chronic hepatitis [Internet]. clinicaltrials.gov; 2022 Jun [cited 2025 Oct 23]. Report No- NCT02499562. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02499562."},{"issue":"1","key":"7449_CR147","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jceh.2019.12.005","volume":"8","author":"CA Philips","year":"2020","unstructured":"Philips CA, Padsalgi G, Ahamed R, Paramaguru R, Rajesh S, George T, et al. Repurposing pirfenidone for nonalcoholic Steatohepatitis-related cirrhosis: a case series. J Clin Transl Hepatol. 2020, Mar, 28;8(1):100\u201305.","journal-title":"J Clin Transl Hepatol"},{"key":"7449_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2017.11.024","volume":"339","author":"O Seniutkin","year":"2018","unstructured":"Seniutkin O, Furuya S, Luo YS, Cichocki JA, Fukushima H, Kato Y, et al. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse. Toxicol Appl Pharmacol. 2018, Jan, 15;339:1\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"key":"7449_CR149","unstructured":"Continent Pharmaceutical Co B, Randomized LA, Double-Blind P-C. Multicenter, Entecavir-based, phase III clinical trial of Hydronidone Capsule in the treatment of liver fibrosis associated with chronic hepatitis B [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Oct 23]. Report No: NCT05115942. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05115942"},{"key":"7449_CR150","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ajt.16978","volume":"22","author":"AJ Kwong","year":"2022","unstructured":"Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN\/SRTR 2020 annual data report: liver. Am J Transpl. 2022, Mar, 1;22:204\u2013309.","journal-title":"Am J Transpl"},{"issue":"1","key":"7449_CR151","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/ajrccm.155.1.9001319","volume":"155","author":"KB Baumgartner","year":"1997","unstructured":"Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997, Jan;155(1):242\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"7449_CR152","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1164\/rccm.200612-1759OC","volume":"177","author":"KM Antoniou","year":"2008","unstructured":"Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008, Jan, 15;177(2):190\u201394.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"7449_CR153","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000481202","volume":"95","author":"B Vainshelboim","year":"2018","unstructured":"Vainshelboim B, Oliveira J, Izhakian S, Unterman A, Kramer MR. Lifestyle behaviors and clinical outcomes in idiopathic pulmonary fibrosis. Respiration. 2018;95(1):27\u201334.","journal-title":"Respiration"},{"issue":"5","key":"7449_CR154","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.chest.2019.10.032","volume":"157","author":"G Sheng","year":"2020","unstructured":"Sheng G, Chen P, Wei Y, Yue H, Chu J, Zhao J, et al. Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis. Chest. 2020, May;157(5):1175\u201387.","journal-title":"Chest"},{"key":"7449_CR155","doi-asserted-by":"publisher","first-page":"240805","DOI":"10.1155\/2011\/240805","volume":"2011","author":"JJ Egan","year":"2011","unstructured":"Egan JJ, Adamali HI, Lok SS, Stewart JP, Woodcock AA. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open Pilot study. Pulm Med. 2011;2011:240805.","journal-title":"Pulm Med"},{"issue":"7","key":"7449_CR156","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/thoraxjnl-2014-206420","volume":"70","author":"S Knippenberg","year":"2015","unstructured":"Knippenberg S, Ueberberg B, Maus R, Bohling J, Ding N, Tarres MT, et al. Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax. 2015, Jul;70(7):636\u201346.","journal-title":"Thorax"},{"issue":"3","key":"7449_CR157","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1378\/chest.129.3.746","volume":"129","author":"CJ Lettieri","year":"2006","unstructured":"Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006, Mar, 1;129(3):746\u201352.","journal-title":"Chest"},{"issue":"8","key":"7449_CR158","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.3346\/jkms.2020.35.e48","volume":"35","author":"J Lee","year":"2020","unstructured":"Lee J, Song JU. The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: systematic review and Meta-analysis of randomized controlled clinical trials. J Korean Med Sci. 2020, Jan, 20;35(8):e48.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"7449_CR159","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, Mar, 15;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"7449_CR160","first-page":"109","volume":"35","author":"B Boonpheng","year":"2018","unstructured":"Boonpheng B, Ungprasert P. Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):109\u201314.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"7449_CR161","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015, Jul, 15;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"7449_CR162","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.chest.2020.10.019","volume":"159","author":"CS King","year":"2021","unstructured":"King CS, Freiheit E, Brown AW, Shlobin OA, Aryal S, Ahmad K, et al. Association between anticoagulation and survival in interstitial lung disease: an analysis of the pulmonary fibrosis foundation patient registry. Chest. 2021, Apr;159(4):1507\u201316.","journal-title":"Chest"},{"issue":"1","key":"7449_CR163","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","volume":"26","author":"Q Lv","year":"2020","unstructured":"Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways. Mol Med. 2020, May, 24;26(1):49.","journal-title":"Mol Med"},{"key":"7449_CR164","unstructured":"Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C. Pirfenidone inhibits transforming growth factor-\u03b21-induced fibrogenesis by blocking nuclear translocation of smads in human retinal pigment epithelial cell line ARPE-19. Mol Vis. 2012, Apr, 21;18:1010\u201320."},{"issue":"1","key":"7449_CR165","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbrc.2008.04.093","volume":"372","author":"Y Mitani","year":"2008","unstructured":"Mitani Y, Sato K, Muramoto Y, Karakawa T, Kitamado M, Iwanaga T, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun. 2008, Jul, 18;372(1):19\u201323.","journal-title":"Biochem Biophys Res Commun"},{"key":"7449_CR166","doi-asserted-by":"crossref","unstructured":"Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: current and future treatment. Clin Respir J. 2022, Jan, 10;16(2):84\u201396.","DOI":"10.1111\/crj.13466"},{"key":"7449_CR167","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021, Dec, 11;21:411.","journal-title":"Bmc Pulm Med"},{"key":"7449_CR168","doi-asserted-by":"crossref","unstructured":"Wu W, Qiu L, Wu J, Liu X, Zhang G. Original research: efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials. BMJ Open [Internet]. 2021;11(12). Available from: [cited 2023 Feb 20]https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8720994.","DOI":"10.1136\/bmjopen-2021-050004"},{"issue":"5","key":"7449_CR169","doi-asserted-by":"publisher","first-page":"e0233732","DOI":"10.1371\/journal.pone.0233732","volume":"15","author":"D Li","year":"2020","unstructured":"Li D, Liu Y, Wang B. Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One. 2020, May, 21;15(5):e0233732.","journal-title":"PLoS One"},{"issue":"5","key":"7449_CR170","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","volume":"332","author":"G Raghu","year":"2024","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, De Salvo MC, Silva RS, Song JW, et al. Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial. Jama. 2024, Aug, 6;332(5):380\u201389.","journal-title":"Jama"},{"key":"7449_CR171","unstructured":"F. A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with idiopathic pulmonary fibrosis (ipf) [Internet]. clinicaltrials.gov; 2024 Sep [cited 2025 Sep 15]. Report No: NCT03955146. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03955146."},{"key":"7449_CR172","unstructured":"F. Zephyrus ii: a phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with idiopathic pulmonary fibrosis (IPF) [Internet]. clinicaltrials.gov; 2024 Aug [cited 2025 Sep 15]. Report No: NCT04419558. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04419558."},{"key":"7449_CR173","unstructured":"Roche H-L. A phase 2 trial to evaluate the efficacy of PRM-151 in subjects with idiopathic pulmonary fibrosis (IPF)[internet]. clinicaltrials.gov; 2022, Mar.[cited 2025 Sep 15]. Report No: NCT02550873. Available from. https:\/\/clinicaltrials.gov\/study\/NCT02550873."},{"issue":"22","key":"7449_CR174","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1001\/jama.2018.6129","volume":"319","author":"G Raghu","year":"2018","unstructured":"Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. Jama. 2018, Jun, 12;319(22):2299\u2013307.","journal-title":"Jama"},{"key":"7449_CR175","unstructured":"Roche H-L. A phase randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis [Internet]. clinicaltrials.gov; 2024 Mar [cited 2025 Sep 15]. Report No.: nCT04552899. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04552899."},{"issue":"9","key":"7449_CR176","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202401-0116OC","volume":"209","author":"L Richeldi","year":"2024","unstructured":"Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, et al. Zinpentraxin Alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial. Am J Respir Crit Care Med. 2024, May, 1;209(9):1132\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"7449_CR177","unstructured":"Roche H-L. A phase III open-label extension study to evaluate long-term safety and efficacy of PRM-151 in patients with idiopathic pulmonary fibrosis (ipf) [Internet]. clinicaltrials.gov; 2024 May [cited 2025 Sep 15]. Report No: NCT04594707. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04594707."},{"key":"7449_CR178","unstructured":"Randomized DSA, D-B. Placebo-controlled phase II clinical trial of GKT137831 in patients with idiopathic pulmonary fibrosis [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Sep 15]. Report No: NCT03865927. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03865927."},{"key":"7449_CR179","unstructured":"Galapagos NA Phase 3, Randomized D-B, Parallel-group, Placebo-controlled, Multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis [Internet]. clinicaltrials.gov; Report No: NCT03733444. Available from: 2022, Jul.[cited 2025 Sep 15] https:\/\/clinicaltrials.gov\/study\/NCT03733444."},{"issue":"18","key":"7449_CR180","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","volume":"329","author":"TM Maher","year":"2023","unstructured":"Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, et al. Ziritaxestat, a novel Autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. Jama. 2023, May, 9;329(18):1567\u201378.","journal-title":"Jama"},{"key":"7449_CR181","unstructured":"Galapagos NV. A phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of Care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis [Internet]. clinicaltrials.gov; Report No.: nCT03711162. Available from: 2022, Jul. [cited 2025 Sep 15] https:\/\/clinicaltrials.gov\/study\/NCT03711162."},{"issue":"22","key":"7449_CR182","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. NEJM Evid. 2025, Jun, 11;392(22):2193\u2013202.","journal-title":"NEJM Evid"},{"key":"7449_CR183","unstructured":"Boehringer Ingelheim. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of bi 1015550 over at least 52 weeks in patients with idiopathic pulmonary fibrosis (ipf) [Internet]. clinicaltrials.gov; 2025 Oct [cited 2025 Oct 23]. Report No.: nCT05321069. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05321069."},{"issue":"1","key":"7449_CR184","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","volume":"595","author":"A Salazar-Montes","year":"2008","unstructured":"Salazar-Montes A, Ruiz-Corro L, L\u00f3pez-Reyes A, Castrej\u00f3n-G\u00f3mez E, Armend\u00e1riz-Borunda J. Potent antioxidant role of Pirfenidone in experimental cirrhosis. Eur J Pharmacol. 2008, Oct, 24;595(1):69\u201377.","journal-title":"Eur J Pharmacol"},{"key":"7449_CR185","doi-asserted-by":"crossref","unstructured":"Wollin L, Togbe D, Ryffel B. Effects of nintedanib in an animal Model of liver fibrosis. Biomed Res Int. 2020; 2020, Mar, 31;3867198.","DOI":"10.1155\/2020\/3867198"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07449-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07449-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07449-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:49:10Z","timestamp":1781624950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07449-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":185,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7449"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07449-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS received grants from Boehringer Ingelheim, Genentech; and is a consultant for Bioclinica, LunglifeAI, AbbVie, Boehringer Ingelheim; and is a speaker for PeerView, France Foundation, Boehringer Ingelheim; and is an editor for the Journal of Translational Medicine. The remaining author reports no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}